Par Pharmaceutical Begins Shipment of Ofloxacin Tablets for Bacterial Infections
SPRING VALLEY, N.Y. -- Pharmaceutical Resources, Inc. announced today that its principal subsidiary, Par Pharmaceutical, has received FDA approval for its ANDA for ofloxacin tablets in 200 mg, 300 mg and 400 mg strengths. Shipment of the 400 mg strength with branded sales of approximately $15 million will begin immediately. It is anticipated the remaining two strengths will ship sometime during the next quarter.
Ofloxacin is the generic version of Ortho-McNeil's Floxin, which is indicated for the treatment of adults with mild to moderate bacterial infections. The Floxin brand has annual sales of approximately $30 million.
Pharmaceutical Resources, Inc., a holding company, develops, manufactures, and distributes generic pharmaceuticals through its wholly owned subsidiary, Par Pharmaceutical.
Source: Par Pharmaceutical
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
